children with hemoglobinopathies undergoing HCT 3, 4 than in those with other conditions. 3, 5 A recent study concluded that hypertension and GVHD were the 2 main risk factors for PRES in patients with hemoglobinopathies while sickle cell disease (SCD) is in higher risks than thalassemia major. 6 However, in our center, hypertension is found to be a common condition after HCT, which makes it difficult to decide whether hypertensive children with thalassemia major should accept the diagnosis process for PRES or early withdraw of CSA and TAC, when presenting suspicious symptoms of PRES and GVHD. Seldom studies have paid attention to the importance of severity of hypertension in PRES. Therefore, this study further evaluated the risk factors and described the features of PRES in children with thalassemia major after HCT.
| MATERIL A S AND ME THODS

| Patients and donors
The study was approved by the Institutions' Ethical Committee, and informed consent was obtained from the patients' parents in Sun
Yat-Sen Memorial Hospital of Sun Yat-Sen University. 84 pediatric patients with thalassemia major who underwent allogeneic HCT between January 2012 and January 2017 were enrolled in this study to assess neurotoxicity (showed as Table 1 Table 1 ).
Total nucleated cell counts (TNC) were 9.6 × 10 8 /kg (range, 
| Transplantation procedures
Details regarding conditioning regimens and graft-versus-host disease (GVHD) prophylaxis are provided in 
| Neurotoxicity assessment
CNIs-associated PRES was diagnosed using the following criteria: 
| Definitions and statistical analysis
The primary objective of this study was to determine the cumulative incidence of PRES in patients with thalassemia major after HCT. Engraftment, acute and chronic GVHD, and supportive care
were defined as described previously. 2 Hypertension was defined as systolic and/or diastolic blood pressure that was equal to or greater than 95th percentile for sex, age, and height measured on 3 or more occasion, while severe hypertension was defined as systolic and/or diastolic blood pressure that was equal to or greater than 99th percentile for sex, age, and height measured on 3 or more occasion. 
| RE SULTS
The ratio of males to females was 62:22, and the median age was 4.0 years(range, 2.0-12.0 years). The graft types were divided into three groups (Table 1) : BM combined with PBSC, PBSC only, and cord blood mixed with BM and/or PBSC. There were 45 cases of unrelated donors, while 39 cases were match sibling donors.
The median of follow-up were 1196 days (ranges, 352-2213 days).
During the follow up, 2 patients died for severe infection 2-3 months after the onset of PRES, while those who died without onset of PRES were excluded. The mortality was believed unrelated to the PRES directly.
The incidence of hypertension was 91.7%, 50.5% of which were severe hypertension. With the presentation of one or more of central neuropathy symptoms, tonic-clonic seizures convulsion (n = 13), mental status changes (n = 15), headache (n = 13), vomiting, blurred vision, dysphoria, 11 children developed PRES associated with CNIs (13.1%), 8 patients while being treated with CSA and 3 patients while being treated with TAC (Table 2 
| Risk factors for PRES
The cumulated incidence of CNIs-associated PRES was 13.4% (95% CI 1.210-9.368; P = 0.020) were associated with PRES (Table 4) . respectively; P = 0.028) ( Figure 1B ). and n = 1,3.3% [95% CI, 0.05%-6.61%], respectively; P = 0.003) ( Figure 1C ). 3 patients who developed PRES while on TAC, 2 were successfully rechallenged with the drug at a low target TAC level of 5-10 ng/mL and 1 patient was switched to sirolimus without subsequent PRES.
TA B L E 2
| Hypertension and PRES
| Pesaro classes and PRES
| Management of PRES
There was no recurrence of seizure after discontinuation valproic acid prophylaxis. The progressive GVHD was not observed in 5 patients. One patient showed Grade I acute GVHD after discontinuation of CSA. Six patients, who were suffering from chronic GVHD at the onset of PRES, presented persistent symptoms of GVHD which was controllable after the switched CNIs.
| D ISCUSS I ON
PRES has been reported to be caused by medicine, such as CSA, 10 TAC, [11] [12] [13] sirolimus. 14, 15 It may also be a complication of diseases, such as systemic lupus erythematosus, 16 acute poststreptococcal glomerulonephritis, 17 neuroblastoma, 18 acute childhood leukemia. 19 The most commonly reported reasons have been CSA and TAC [11] [12] [13] therapy after different types of transplantation. 10,11 PRES was reported due to pulse MP therapy in a child 20 and was thought as a possible complication of renal disease and hypertensive crisis. 21 Infection 22 could be trigger. Most of the cases prognosis well, except for a few cases of prolonged symptoms or death. 23 The mechanisms of PRES are unclear; however, immunosuppression and hypertension are said strongly associated with it. Suggested hypotheses include cerebral vasoconstriction with ischemia/infarct of brain tissue, failure of cerebral autoregulation with vasogenic edema, and endothelial damage with disruption of the blood-brain barrier resulting in fluid transudation. [24] [25] [26] Status epilepticus, which could be life-threatening, is the main manifestation of PRES after pediatric HCT. 27 There is necessity to interrupt the development fatal sequela by early recognition and prophylaxis PRES, through identification of risk factors for PRES in HCT. The reported incidence of PRES in children after HCT could be related to the conditioning regimen, underlying hematologic disease, type of transplantation, immunosuppressive drugs, hypertension, and GVHD. 3, 25, 28 Yet no published reports have reported the severe hypertension was related to increased risks of PRES in patients with thalassemia major.
This present study confirmed PRES was multifactorial, and factors such as severe hypertension, activated GVHD, and Pesaro score played important roles in PRES development in patients of thalassemia major after HCT. Severe hypertension and Pesaro 3 were risk factors for high incidence of PRES in our study which was different from previous studies.
A recent study concluded that hypertension and GVHD were the 2 main risk factors for PRES in patients with hemoglobinopathies while sickle cell disease (SCD) was in higher risks than thalassemia major. 6 However, in our center, hypertension was found to be a common condition after HCT, which made it difficult to decide whether hypertensive children with thalassemia major should accept the diagnosis process for PRES or early withdraw of CSA and TAC, when presenting suspicious symptoms of PRES and GVHD. Seldom studies have paid attention to the importance of severity of hypertension in PRES.
The cohort in Gaziev's study 6 was quite different from this present study in the aspects of Pesaro 3 proportion, haploidentical donors, T-cell deplete. Furthermore, the MP dose was ≤0.5 mg/kg in some patients in the previous study, 6 while in our center, at the onset of GVHD, dose of MP was ≥1.0 mg/kg. The conditioning regimens, which were believed to be responsible for the development of PRES, CMV indicates cytomegalovirus; PBSC, peripheral blood stem cell; BM, bone marrow; UCB, umbilical cord blood; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; ATG, antithymocyte globulin. potential mechanism of immune system activation and endothelial dysfunction might play a critical role in the pathogenesis of PRES, 29 explaining the phenomenon that 10/11 PRES were started during activated either acute or chronic GVHD. Haploidentical donor would indicate higher risks of T-cell activation after HCT leading to compounding factors to the Gaziev's study.
The diagnosis of PRES has depended on the brain MRI which most frequently showed variable lesion patterns. 30 In a retrospective study on 220 patients, only seventeen percent of patients had a radiologically confirmed diagnosis of PRES. Epileptic seizures, encephalopathy, visual disturbances, hypertension, renal failure, and chemotherapy were the clinical predictors of PRES, while headache, immune suppression, and autoimmune disease were not useful for the clinical diagnosis of PRES. 30 Post-transplantation has been reported as a factor associated with poor outcomes for PRES. 31 Abnormal MRI findings in late stages were associated with neurological sequelae. All transplant recipients with symptoms consistent with PRES should be promptly recognized to avoid long-term complications or even death. 32 Recognition of early signals for PRES would be valuable for prevention of sequelae.
Hypertension incidence was high in our study, and it was not significantly related to the incidence of PRES, which was different from the previous reports. 6, 33, 34 However, according to our data, the reasons for this phenomenon were not found out and further research would be needed. Interestingly, we found that the se- Previous reports showed that at the time of PRES, about half of the patients had acute grades II to IV GVHD. The incidence of PRES was significantly higher in patients who had grades I to IV acute GVHD than in patients without GVHD, 6 which was similarly showed as our data. The rate of PRES was significantly higher in patients with GVHD than in those without GVHD. Both acute GVHD and chronic GVHD were associated with the application of higher dose of CNIs, as well as the higher dose of MP, both of which were likely to stimulate the severe hypertension.
Pesaro risk factors were designed for the prognosis of thalassemia major transplantation. In this presenting data, higher Pesaro class indicated the higher risks of PRES, which was controversial to the recent study by Gaziev et al; however, this present study was different from the Gaziev's study. We did not share the similar conditioning regimens. For Pesaro 3 patients, Cy dose was adjusted to 180 mg/kg, while TNC was increased to 11 × 10 8 /kg in BMT and/or PBSCT. UCBT was not performed for this group. The risk of GVHD was increased. So was the risk of PRES. Another explanation for this result was the immune system activation and endothelial dysfunction 29 in thalassemia major whose relation with PRES needed further study.
Both antifungal therapy and azole were related to the higher risks of PRES as showed in univariate analysis. Antifungal therapy meant coexisted infections which could be the trigger of PRES, 22 and would induce T-cell activation, cytokine release, and subsequent leukocyte adhesion and activation, resulting in endothelial damage and fluid leakage 29 
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